Cox John
CEO & President at DYN; Director at RGEN; EVP Pharmaceutical Oper & Tech at BIIB
- Sold, on record
- $15.3M
- Dollars the filings state
- Form 4 sales
- 24
- Latest Sep 8, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 3
- Filed as an executive or holder
Companies
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale DYNRoutineJun 5 2025
Sold 4,060 shares at $13.35 ($54k)
Cox John, CEO & President
10b5-1 planSold 2.8% of holdings ($2M position)142,179 shares leftFiling
- 2 Form 4 sale DYNRoutineSep 5 +92 days
Sold 2,640 shares at $13.41 ($35k)
Cox John, CEO & President
10b5-1 planSold 1.3% of holdings ($2.7M position)199,539 shares leftFiling
- 3 Form 4 sale DYNRoutineDec 5 +91 days
Sold 2,662 shares at $20.72 ($55k)
Cox John, CEO & President
10b5-1 planSold 1.3% of holdings ($4.1M position)196,877 shares left0.7x usual sizeFiling
- 4 Form 4 sale DYNRoutineMar 5 +90 days
Sold 2,732 shares at $14.90 ($41k)
Cox John, CEO & President
10b5-1 planSold 0.7% of holdings ($5.6M position)374,145 shares left0.8x usual sizeFiling
- 5 Form 4 sale DYNRoutineMay 13 +69 days
Sold 3,311 shares at $18.36 ($61k)
Cox John, CEO & President
10b5-1 planSold 0.9% of holdings ($6.9M position)370,834 shares left1.2x usual sizeFiling
- 6 Form 4 sale DYNRoutineJun 16 +34 days
Sold 2,683 shares at $18.33 ($49k)
Cox John, CEO & President
10b5-1 planSold 0.7% of holdings ($6.8M position)368,151 shares left0.9x usual sizeFiling
- 7 Form 4 sale DYNRoutineAug 13 +58 days
Sold 4,986 shares at $26.28 ($131k)
Cox John, CEO & President
10b5-1 planSold 1.4% of holdings ($9.7M position)363,165 shares left1.8x usual sizeFiling
- 8 Form 4 sale DYNRoutineSep 8 +26 days
Sold 5,658 shares at $18.88 ($107k)
Cox John, CEO & President
10b5-1 planSold 1.6% of holdings ($6.9M position)357,507 shares left1.9x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (24)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | DYN | CEO & President | Form 4 sale | 5,658 | $107k | 1.6% | Routine | SEC |
| Aug 13, 2026 | DYN | CEO & President | Form 4 sale | 4,986 | $131k | 1.4% | Routine | SEC |
| Jun 16, 2026 | DYN | CEO & President | Form 4 sale | 2,683 | $49k | 0.7% | Routine | SEC |
| May 13, 2026 | DYN | CEO & President | Form 4 sale | 3,311 | $61k | 0.9% | Routine | SEC |
| Mar 5, 2026 | DYN | CEO & President | Form 4 sale | 2,732 | $41k | 0.7% | Routine | SEC |
| Dec 5, 2025 | DYN | CEO & President | Form 4 sale | 2,662 | $55k | 1.3% | Routine | SEC |
| Sep 5, 2025 | DYN | CEO & President | Form 4 sale | 2,640 | $35k | 1.3% | Routine | SEC |
| Jun 5, 2025 | DYN | CEO & President | Form 4 sale | 4,060 | $54k | 2.8% | Routine | SEC |
| Mar 5, 2025 | DYN | CEO & President | Form 4 sale | 4,061 | $48k | 2.7% | Routine | SEC |
| Mar 24, 2020 | RGEN | Director | Form 4 sale | 1,858 | $180k | 66.8% | Unusual | SEC |
| Mar 18, 2020 | RGEN | Director | Form 4 sale | 26,736 | $2.5M | 90.6% | Unusual | SEC |
| Mar 4, 2020 | RGEN | Director | Form 4 sale | 10,000 | $934k | 78.2% | Unusual | SEC |
| Feb 24, 2020 | RGEN | Director | Form 4 sale | 4,455 | $413k | 61.6% | Unusual | SEC |
| Mar 25, 2015 | BIIB | EVP Pharmaceutical Oper & Tech | Form 4 sale | 12,010 | $5.4M | 32.0% | Unusual | SEC |
| Nov 1, 2011 | BIIB | EVP Pharmaceutical Oper & Tech | Form 4 sale | 2,175 | $249k | 18.5% | Plan not stated | SEC |
| Apr 21, 2011 | BIIB | EVP Pharmaceutical Oper & Tech | Form 4 sale | 4,350 | $435k | 29.6% | Unusual | SEC |
| Apr 13, 2011 | BIIB | EVP Pharmaceutical Oper & Tech | Form 4 sale | 36,234 | $2.9M | 77.8% | Unusual | SEC |
| Apr 11, 2011 | BIIB | EVP Pharmaceutical Oper & Tech | Form 4 sale | 6,900 | $538k | 40.0% | Unusual | SEC |
| Mar 31, 2011 | BIIB | EVP Pharmaceutical Oper & Tech | Form 4 sale | 2,840 | $207k | 22.4% | Plan not stated | SEC |
| Mar 2, 2011 | BIIB | EVP Pharmaceutical Oper & Tech | Form 4 sale | 4,041 | $283k | 29.2% | Unusual | SEC |
| Feb 17, 2011 | BIIB | EVP Pharmaceutical Oper & Tech | Form 4 sale | 1,843 | $124k | 11.9% | Plan not stated | SEC |
| Nov 9, 2010 | BIIB | EVP Pharmaceutical Oper & Tech | Form 4 sale | 773 | $49k | 4.5% | Plan not stated | SEC |
| Nov 2, 2010 | BIIB | EVP Pharmaceutical Oper & Tech | Form 4 sale | 765 | $48k | 4.3% | Plan not stated | SEC |
| Oct 28, 2010 | BIIB | EVP Pharmaceutical Oper & Tech | Form 4 sale | 6,900 | $435k | 27.4% | Unusual | SEC |